Shares of Inovio are down about 2% in premarket trading after reports surfaced of the cancellation of a six-year-old development agreement for a DNA cancer vaccine collaboration related to human papillomavirus with AstraZeneca. In a U.S. Securities and Exchange filing, Inovio…
